Menu

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2019

  1. 06/08/2019
    MorphoSys AG Reports Second Quarter 2019 Financial Results
  2. 06/08/2019
    MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL
  3. 06/08/2019
    MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency
  4. 25/07/2019
    Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019
  5. 08/07/2019
    MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology
  6. 03/07/2019
    MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
  7. 24/06/2019
    MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
  8. 24/06/2019
    Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available
  9. 22/06/2019
    MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
  10. 14/06/2019
    MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2018

  1. 19/07/2018
    Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018
    No download available
  2. 18/04/2018
    Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
  3. 09/04/2018
    Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States
  4. 22/03/2018
    Ad hoc: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering

2017

  1. 30/11/2017
    Ad hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
    No download available
  2. 23/10/2017
    Ad hoc: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
    No download available
  3. 21/07/2017
    Ad hoc: MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma
    No download available
  4. 13/07/2017
    Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis
    No download available

2016

  1. 15/11/2016
    Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
  2. 15/11/2016
    Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares

Pages

Presentations
and conferences

Tuesday, December 3, 2019
31st Annual Piper Jaffray Healthcare Conference

Dr. Jean-Paul Kress presented the company at the 31st Annual Piper Jaffray Healthcare Conference in New York, NY, US.

DocumentFile info
Company Update 1.85 MB

Archive

Date
Title
MP3

2019

  1. 12/03/2019

    31st Annual Piper Jaffray Healthcare Conference

  2. 11/25/2019

    Presentation: German Eigenkapitalforum

  3. 10/30/2019

    Conference Call and Webcast: Q3 2019 Financial Results

  4. 09/25/2019

    Presentation: 8th Annual Goldman Sachs and Berenberg German Corporate Conference

  5. 08/27/2019

    Presentation: Commerzbank Sector Conference 2019

  6. 08/07/2019

    Conference Call and Webcast: Q2 2019 Financial Results

  7. 06/25/2019

    Webcast: Meet the Team

  8. 06/22/2019

    Presentation: ICML in Lugano

  9. 06/12/2019

    Presentation: Goldman Sachs 40th Annual Global Healthcare Conference

  10. 06/06/2019

    Presentation: dbAccess

  11. 06/05/2019

    Webcast: Jefferies Healthcare Conference

  12. 05/20/2019

    Conference call: Q&A session on the headline data of tafasitamab (MOR208)

  13. 05/08/2019

    Conference Call and Webcast: Q1 2019 Financial Results

  14. 04/26/2019

    Presentation: Class of 2018 Biotech IPOs Investor Day

  15. 04/16/2019

    Presentation: Kempen Life Sciences Conference

  16. 03/14/2019

    Year-End 2018 Conference Call and Webcast

  17. 02/28/2019

    Webcast: 8th Annual Leerink Partners Global Healthcare Conference

  18. 01/21/2019

    Presentation: Kepler Chevreux German Corporate Conference

  19. 01/14/2019

    Presentation: Commerzbank German Investment Seminar 2019

  20. 01/09/2019

    Webcast: JPMorgan Annual Healthcare Conference 2019

Pages

Pictures

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".